Market revenue in 2021 | USD 458.2 million |
Market revenue in 2030 | USD 3,091.4 million |
Growth rate | 23.6% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.61% in 2021. Horizon Databook has segmented the North America non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
High growth of non-alcoholic steatohepatitis biomarkers market in North America can be attributed to various factors such as rising prevalence of diabetes and obesity coupled with favorable government initiatives. Funding for R&D of biomarkers is high in the region.
Furthermore, increasing demand for personalized medicine for Non-Alcoholic Steatohepatitis (NASH) is expected to positively impact the growth of North America non-alcoholic steatohepatitis biomarkers market. Moreover, government regulations in North America support R&D of novel biomarkers.
Major players operating in this market include GENFIT, Prometheus Laboratories, and Bristol-Myers Squibb Company. Local presence of such leading companies is expected to increase the availability of novel biomarkers in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into North America non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account